VPS4A Mutations in Humans Cause Syndromic Congenital Dyserythropoietic Anemia due to Cytokinesis and Trafficking Defects. The American Journal of Human Genetics. 2020; 107:1149-1156.
.Red cell membrane disorders: structure meets function. Blood. 2020; 136:1250-1261.
.Signaling and cytoskeletal requirements in erythroblast enucleation. Blood. 2012; 119:6118-6127.
.Hemolytic anemia and macrothrombocytopenia: A lipid problem?. American Journal of Hematology. 2023; 98:1335-1340.
.Crosstalk between terminal erythropoiesis and granulopoiesis within their common niche: the erythromyeloblastic island. Current Opinion in Hematology. 2023; 30:99-105.
.Navigating the marrow sea towards erythromyeloblastic islands under normal and inflammatory conditions. Current Opinion in Hematology. 2023; 30:80-85.
.Pediatric myelofibrosis due to compound heterozygous MPIG6B mutations in a patient of European ancestry. Pediatric Blood and Cancer. 2023; 70:e30023.
.Mutations in the RACGAP1 gene cause autosomal recessive congenital dyserythropoietic anemia type III. Haematologica: the hematology journal. 2023; 108:581-587.
.M-CSF supports medullary erythropoiesis and erythroid iron demand following burn injury through its activity on homeostatic iron recycling. Scientific Reports. 2022; 12:1235.
.2022; 140:1234-1235.
. De Novo Germline DHX38 Variant Associated with Alternative Splicing of Multiple Transcripts in Iron-Related Pathways in a Patient with Atypical Congenital Dyserythropoietic Anemia with Ring Sideroblasts. Blood.2022; 140:8190-8191.
. Dominant-Negative VPS4A Mutations Causing Congenital Dyserythropoietic Anemia Disrupt Iron Trafficking of Terminal Erythropoiesis. Blood.Erythroblastic islands foster granulopoiesis in parallel to terminal erythropoiesis. Blood. 2022; 140:1621-1634.
.2022; 22:s160.
. Poster: MPN-024 Hypereosinophilic Syndrome: A Catastrophic Pediatric Case. Clinical Lymphoma, Myeloma and Leukemia.Insane in the membrane: A case of hereditary spherocytic pyropoikilocytosis. American Journal of Hematology. 2022; 97:1384-1385.
.MPN-024 Hypereosinophilic Syndrome: A Catastrophic Pediatric Case. Clinical Lymphoma, Myeloma and Leukemia. 2022; 22 Suppl 2:S322.
.2022; 6:02-03.
. O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH. HemaSphere.2022; 6:43-44.
. P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE. HemaSphere.Autism-associated chromatin remodeler CHD8 regulates erythroblast cytokinesis and fine-tunes the balance of Rho GTPase signaling. Cell Reports. 2022; 40:111072.
.Rapid degradation of protein tyrosine phosphatase 1B in sickle cells: Possible contribution to sickle cell membrane weakening. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2022; 36:e22360.
.Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial. Clinical Pharmacology in Drug Development. 2022; 11:654-665.
.Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. The Journal of pharmacology and experimental therapeutics. 2022; 380:210-219.
.Altered erythropoiesis in newborns with congenital heart disease. Pediatric Research. 2022; 91:606-611.
.Diagnosis and clinical management of red cell membrane disorders. Hematology-American Society of Hematology Education Program. 2021; 2021:331-340.
.Characterizing bulk rigidity of rigid red blood cell populations in sickle-cell disease patients. Scientific Reports. 2021; 11:7909.
.Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response. Blood Cells, Molecules, and Diseases. 2021; 90:102576.
.Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. British Journal of Haematology. 2021; 194:617-625.
.Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature. 2021; 595:295-302.
.Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience. Pediatric Blood and Cancer. 2021; 68:e29008.
.Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia. Frontiers in Physiology. 2021; 12:636609.
.Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR). Blood Cells, Molecules, and Diseases. 2021; 87:102534.
.Rasa3 regulates stage-specific cell cycle progression in murine erythropoiesis. Blood Cells, Molecules, and Diseases. 2021; 87:102524.
.ER-to-Golgi transport and SEC23-dependent COPII vesicles regulate T cell alloimmunity. The Journal of Clinical Investigation. 2021; 131:e136574.
.Autoimmune Hemolytic Anemia in the Pediatric Setting. Journal of Clinical Medicine. 2021; 10:E216.
.VPS4A Mutations in Humans Cause Syndromic Congenital Dyserythropoietic Anemia due to Cytokinesis and Trafficking Defects. The American Journal of Human Genetics. 2020; 107:1149-1156.
.A painless erythematous swelling of the external ear as a manifestation of Lyme disease: a case report. Journal of Medical Case Reports. 2020; 14:48.
.2020; 136:16-17.
. Rapid and Automated Quantitation of Dense Red Blood Cells: A Robust Biomarker of Therapeutic Response to Early Initiation of Hydroxyurea in Young Children with Sickle Cell Anemia. Blood.2020; 136:31-32.
. Angiotensin Signaling Is Essential for Stress Erythropoiesis but Results in Retention of Dysfunctional Mitochondria in Erythrocytes That Generate Excessive Reactive Oxygen Species. Blood.2020; 136:19-20.
. FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease. Blood.How I approach hereditary hemolytic anemia and splenectomy. Pediatric Blood and Cancer. 2020; 67:e28337.
.Red cell membrane disorders: structure meets function. Blood. 2020; 136:1250-1261.
.LONG-TERM HEMATOLOGIC AND CLINICAL OUTCOMES OF SPLENECTOMY IN CHILDREN WITH HEREDITARY SPHEROCYTOSIS AND SICKLE CELL DISEASE. Pediatric Blood and Cancer. 2020; 67:e28290.
.Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell disease. British Journal of Haematology. 2020; 190:599-609.
.2020; 204:63.1.
. Novel role(s) for Irf5 in controlling myelopoiesis and erythropoiesis. Journal of immunology (Baltimore, Md. : 1950).2019; 134:3521.
. Congenital Dyserythropoietic Anemia Type I Due to Biallelic CDAN1 mutations: Report from the Congenital Dyserythropoietic Anemia Registry (CDAR). Blood.Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. American Journal of Hematology. 2019; 94:871-879.
.The Spectrum of SPTA1-Associated Hereditary Spherocytosis. Frontiers in Physiology. 2019; 10:815.
.Rare Hereditary Hemolytic Anemias: Diagnostic Approach and Considerations in Management. Hematology/Oncology Clinics of North America. 2019; 33:373-392.
.Hereditary elliptocytosis-associated alpha-spectrin mutation p.L155dup as a modifier of sickle cell disease severity. Pediatric Blood and Cancer. 2019; 66:e27531.
.Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency. American Journal of Hematology. 2019; 94:149-161.
.Springer Nature; Springer Nature; 2019.
. Acquired Hemolytic Anemias. Concise Guide to Hematology. :